Details
Stereochemistry | ACHIRAL |
Molecular Formula | C4H7NO3.C2H3Cl3O2 |
Molecular Weight | 282.506 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(O)C(Cl)(Cl)Cl.CC(=O)NCC(O)=O
InChI
InChIKey=SULCNWZLMZPENK-UHFFFAOYSA-N
InChI=1S/C4H7NO3.C2H3Cl3O2/c1-3(6)5-2-4(7)8;3-2(4,5)1(6)7/h2H2,1H3,(H,5,6)(H,7,8);1,6-7H
Molecular Formula | C4H7NO3 |
Molecular Weight | 117.1033 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C2H3Cl3O2 |
Molecular Weight | 165.403 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/ppa/chloral-hydrate.htmlCurator's Comment: description was created based on several sources, including
http://www.rxlist.com/noctec-drug/clinical-pharmacology.htm |
https://www.ncbi.nlm.nih.gov/pubmed/7834208
Sources: https://www.drugs.com/ppa/chloral-hydrate.html
Curator's Comment: description was created based on several sources, including
http://www.rxlist.com/noctec-drug/clinical-pharmacology.htm |
https://www.ncbi.nlm.nih.gov/pubmed/7834208
Chloral hydrate was discovered in 1832, and was used as a sedative in late 19th century. Chloral hydrate has not been approved by the FDA or the EMA, and is on the list of unapproved drugs that are prescribed for postoperative pain control, sedation and to prevent alcohol withdrawal and reduce anxiety associated with withdrawal of opiates or barbiturates. Mechanism of action of chloral hydrate is not known. It is generally believed that the central depressant effects are due to the principal pharmacologically active metabolite trichloroethanol, which has a plasma half- life of 8 to 10 hours, and acts by potentiating GABA-activated Cl currents.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7834208 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseAdjunct to opiates and analgesics for postoperative pain control |
|||
Primary | Unknown Approved UseShort-term sedative and hypnotic (<2 weeks) |
|||
Primary | Unknown Approved UseSedative/hypnotic for diagnostic procedures; sedative prior to EEG evaluations |
|||
Preventing | Unknown Approved UseMonotherapy or concomitant with paraldehyde for prevention of alcohol withdrawal symptoms and/or to suppress syndrome once it develops |
|||
Palliative | Unknown Approved UseReduction of anxiety associated with withdrawal of opiates or barbiturates |
PubMed
Title | Date | PubMed |
---|---|---|
Use of subjective responses to evaluate efficacy of mild analgesic-sedative combinations. | 1974 Feb |
|
The efficacy of triazolam and chloral hydrate in geriatric insomniacs. | 1980 |
|
Trichloroethanol potentiation of gamma-aminobutyric acid-activated chloride current in mouse hippocampal neurones. | 1994 Oct |
|
Acute drug administration in epilepsy: a review. | 2011 Oct |
|
The safety and efficacy of chloral hydrate sedation for pediatric ophthalmic procedures: a retrospective review. | 2014 May-Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/ppa/chloral-hydrate.html
Sedation, anxiety: Oral: 250 mg 3 times daily. Hypnotic: Oral: 500-1000 mg 15-30 minutes before bedtime or 30 minutes prior to procedure, not to exceed 2000 mg per 24 hours.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:31:08 GMT 2023
by
admin
on
Fri Dec 15 15:31:08 GMT 2023
|
Record UNII |
6WZ3595RLZ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N05CC03
Created by
admin on Fri Dec 15 15:31:08 GMT 2023 , Edited by admin on Fri Dec 15 15:31:08 GMT 2023
|
||
|
WHO-VATC |
QN05CC03
Created by
admin on Fri Dec 15 15:31:08 GMT 2023 , Edited by admin on Fri Dec 15 15:31:08 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL3707308
Created by
admin on Fri Dec 15 15:31:08 GMT 2023 , Edited by admin on Fri Dec 15 15:31:08 GMT 2023
|
PRIMARY | |||
|
4316
Created by
admin on Fri Dec 15 15:31:08 GMT 2023 , Edited by admin on Fri Dec 15 15:31:08 GMT 2023
|
PRIMARY | |||
|
DTXSID00169803
Created by
admin on Fri Dec 15 15:31:08 GMT 2023 , Edited by admin on Fri Dec 15 15:31:08 GMT 2023
|
PRIMARY | |||
|
Acetylglycinamide chloral hydrate
Created by
admin on Fri Dec 15 15:31:08 GMT 2023 , Edited by admin on Fri Dec 15 15:31:08 GMT 2023
|
PRIMARY | |||
|
6WZ3595RLZ
Created by
admin on Fri Dec 15 15:31:08 GMT 2023 , Edited by admin on Fri Dec 15 15:31:08 GMT 2023
|
PRIMARY | |||
|
71587019
Created by
admin on Fri Dec 15 15:31:08 GMT 2023 , Edited by admin on Fri Dec 15 15:31:08 GMT 2023
|
PRIMARY | |||
|
17427-14-4
Created by
admin on Fri Dec 15 15:31:08 GMT 2023 , Edited by admin on Fri Dec 15 15:31:08 GMT 2023
|
PRIMARY | |||
|
DB13402
Created by
admin on Fri Dec 15 15:31:08 GMT 2023 , Edited by admin on Fri Dec 15 15:31:08 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |